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ARTICLE OPEN
High-resolution bacterial 16S rRNA gene proﬁle meta-analysis
and bioﬁlm status reveal common colorectal cancer consortia
Julia L. Drewes 1, James R. White2, Christine M. Dejea1, Payam Fathi1, Thevambiga Iyadorai3, Jamuna Vadivelu3, April C. Roslani 3,
Elizabeth C. Wick1, Emmanuel F. Mongodin4, Mun Fai Loke3, Kumar Thulasi3, Han Ming Gan5, Khean Lee Goh3, Hoong Yin Chong3,
Sandip Kumar3, Jane W. Wanyiri1 and Cynthia L. Sears1
Colorectal cancer (CRC) remains the third most common cancer worldwide, with a growing incidence among young adults. Multiple
studies have presented associations between the gut microbiome and CRC, suggesting a link with cancer risk. Although CRC
microbiome studies continue to proﬁle larger patient cohorts with increasingly economical and rapid DNA sequencing platforms,
few common associations with CRC have been identiﬁed, in part due to limitations in taxonomic resolution and differences in
analysis methodologies. Complementing these taxonomic studies is the newly recognized phenomenon that bacterial organization
into bioﬁlm structures in the mucus layer of the gut is a consistent feature of right-sided (proximal), but not left-sided (distal)
colorectal cancer. In the present study, we performed 16S rRNA gene amplicon sequencing and bioﬁlm quantiﬁcation in a new
cohort of patients from Malaysia, followed by a meta-analysis of eleven additional publicly available data sets on stool and tissue-
based CRC microbiota using Resphera Insight, a high-resolution analytical tool for species-level characterization. Results from the
Malaysian cohort and the expanded meta-analysis conﬁrm that CRC tissues are enriched for invasive bioﬁlms (particularly on right-
sided tumors), a symbiont with capacity for tumorigenesis (Bacteroides fragilis), and oral pathogens including Fusobacterium
nucleatum, Parvimonas micra, and Peptostreptococcus stomatis. Considered in aggregate, species from the Human Oral Microbiome
Database are highly enriched in CRC. Although no detected microbial feature was universally present, their substantial overlap and
combined prevalence supports a role for the gut microbiota in a signiﬁcant percentage (>80%) of CRC cases.
npj Bioﬁlms and Microbiomes  (2017) 3:34 ; doi:10.1038/s41522-017-0040-3
INTRODUCTION
While numerous environmental risk factors for colorectal cancer
(CRC) were established decades ago,1 only in recent years have we
begun to appreciate the role of the gut microbiome in CRC. Over a
dozen studies have now established that CRC is associated with
some form of microbial dysbiosis in terms of taxonomic
composition and/or mucosal structural organization (e.g., bio-
ﬁlms), as detected either via stool or tumor tissue.2–16 However,
these CRC microbiome proﬁling studies have yielded inconsistent
ﬁndings, likely due to differences in study design and analysis
methodologies. Furthermore, the relative contribution of mucosal
vs. luminal (i.e., stool) populations, known to differ,17 is uncertain.
In the present study, we analyzed the taxonomic composition and
bioﬁlm status of both previous and new cohorts in order to
present a more robust depiction of the contribution of the
microbiota to CRC.
RESULTS
Conﬁrmation of the bioﬁlm-spatial relationship in CRC
We ﬁrst sought to validate previous ﬁndings that invasive bioﬁlms
are a feature of right-sided (proximal) CRC, originally described in
a USA cohort (USA, N = 36) and a Malaysian cohort (MAL1,
N = 22).16 Bioﬁlms form when bacteria aggregate on a surface
(biological or inert) and become encased in a polymeric
matrix.18,19 Similar to other in vivo bioﬁlms including oral bioﬁlms
(dental plaque) and Pseudomonas aeruginosa bioﬁlms in cystic
ﬁbrosis patients, the colonic bioﬁlm matrix may consist of both
host mucus and bacteria-produced extrapolymeric substrates.20,21
The invasion and attachment of bioﬁlms to the colonic epithelium
and inner mucus layer can be visualized by a number of different
microscopy-based methodologies including ﬂuorescence in situ
hybridization (FISH) staining with oligonucleotide ﬂuorescent
probes, electron microscopy, or acridine orange staining.22,23
Tumor and paired normal samples from a new cohort of 23
patients in Malaysia who underwent surgical resection (described
hereafter as MAL2; see Supplementary Table S1 for metadata)
were thus screened by FISH with the Eub338 universal 16S rRNA
gene probe, using slides from tissue blocks ﬁxed in Carnoy’s to
preserve the mucus layer. Paired normal samples were taken from
a non-cancerous region of the resected colorectal sample as far as
possible from the tumor itself (Supplementary Fig. S1a). Repre-
sentative bioﬁlm-positive (right-sided) and bioﬁlm-negative (left-
sided) tissues from MAL2 are shown in Fig. 1a. A total of 6/16 left-
sided tumors from MAL2 were bioﬁlm positive (37.5%), while all
seven right-sided tumors were bioﬁlm positive (100%). Bioﬁlm
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Fig. 1 Meta-analysis of bioﬁlm prevalence in CRC. a Microbial bioﬁlms in Carnoy’s-ﬁxed tissue were detected by FISH with the universal 16S
rRNA gene probe Eub338 (stained in red) and the nucleic acid stain DAPI (blue). White brackets denote the mucus layer, visible via
autoﬂuorescence of the tissue. Left panel: a bioﬁlm-positive paired normal tissue from the right colon of a CRC patient with abundant bacteria
adjacent to the epithelium (arrow). Right panel: a bioﬁlm-negative paired normal tissue from the left colon of a CRC patient with minimal
bacteria (arrow) present only in the outer edge of the mucus. Scale bars represent 100 μm. b The locations of tumors from USA, MAL1, and
MAL2 are overlaid on a diagram of the colon. c Percentage of bioﬁlm-positive right and left tumors for the three cohorts. All statistics shown
are Fisher’s exact tests. d Total percentage of bioﬁlm-positive right- and left-sided tumors from all three cohorts is depicted with a Fisher’s
exact test p-value. e Left-sided and right-sided tumors separated according to tumor stage and bioﬁlm status. Multivariate logistic regression
analysis was performed after controlling for tumor side. f, g Bioﬁlm-positive samples were stained with DAPI (blue) and probes against four
bacterial membership groups: Fusobacterium (yellow), Bacteroidetes (green), Lachnospiraceae (red), and Proteobacteria (magenta). Scale bars
in large images represent 100 μm; scale bars in smaller, inset images represent 5 μm. f Representative polymicrobial bioﬁlm from a tumor (left
panel) and its paired normal tissue (right panel), with blooms of Fusobacterium in yellow visible only in the tumor. g Representative
Proteobacteria-dominant tumor (left panel) and its paired normal tissue (right panel)
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results for MAL2 were then combined with the previously
published USA and MAL1 cohorts.16 The spatial distribution of
tumors and their bioﬁlm status for all three cohorts are depicted in
Fig. 1b. Individual study tumor maps are shown in Supplementary
Fig. S1b. Each study individually had a signiﬁcantly higher
prevalence of bioﬁlms on right-sided tumors by Fisher’s exact
test (Fig. 1c; USA p < 0.0001; MAL1 p = 0.029; MAL2 p = 0.008), as
did the combined analysis of all three studies (Fig. 1d, p < 0.0001).
However, the Malaysian cohorts MAL1 and MAL2 had approxi-
mately a 3-fold higher prevalence of bioﬁlms on left-sided tumors
than the USA cohort (33% for MAL1, 38% for MAL2, and 12% for
USA), which may reﬂect differences in diet/lifestyle, genetics, or
the native microbial environment of the two countries. As
previously reported for the USA cohort, the bioﬁlm status of
paired normal tissues from MAL1 and MAL2 largely matched the
bioﬁlm status of the tumors from the same individual and
therefore were called concordant pairs; only 2/21 MAL1 and 3/23
MAL2 patients had discordant bioﬁlm scores between their tumor
and normal tissues, all 5 of which were cases in which the tumor
was bioﬁlm positive but the paired normal tissue was negative.
Multivariate logistic regression analysis revealed that tumor stage
[N = 74 cancers, excluding surgical polyps (6 from USA; 1 from
MAL1)] was not signiﬁcantly associated with bioﬁlm status after
controlling for tumor side (Fig. 1e, right tumors p > 0.48 for all
stages; left tumors p > 0.19 for all stages).
The concordant tumor-normal bioﬁlm-positive pairs from MAL1
(nine pairs) and MAL2 (ten pairs) were subsequently examined by
multi-probe FISH with probes against four taxonomic groups that
were previously found to be the dominant bacterial members of
bioﬁlms in the USA cohort: phylum Bacteroidetes (including
Bacteroides, Parabacteroides, and Prevotella), genus Fusobacterium,
family Lachnospiraceae, and the classes Gamma- and Betaproteo-
bacteria. As with the USA cohort, the Malaysian bioﬁlms tended to
be polymicrobial, with an abundance of Lachnospiraceae,
Bacteroidetes, and Proteobacteria in both tumor and normal
tissues from 17/19 patients. Fusobacterium was also detectable in
almost all (16/17) tumors with polymicrobial bioﬁlms, ranging
from sparse populations (less than 5 bacteria visible in a 200 μm×
200 μm ﬁeld of view) in the majority of tumors to dense blooms in
4/17 of the bioﬁlm-positive tumors (Fig. 1f). In contrast, paired
normal tissues were largely devoid of Fusobacterium (Fig. 1f).
Sequencing analyses (see subsequent sections) from frozen
tissues of the same patients revealed that F. nucleatum was often
the most abundant fusobacterial species detected in these tissues.
The remaining two patients’ bioﬁlms consisted exclusively of
Proteobacteria in both the tumor and paired normal tissue
(representative tumor/normal staining shown in Fig. 1g). Thus,
tumors and paired normal tissues were largely concordant with
respect to both bioﬁlm status and bioﬁlm composition with the
exception of Fusobacterium, which was largely present only in
tumor bioﬁlms.
Microbial taxa and functions associated with bioﬁlm status
To complement the results of bioﬁlm quantiﬁcation, we next
sought to identify microbial members associated with bioﬁlm-
positive status. Traditional analyses of 16S rRNA gene sequencing
data have been limited to genus-level identiﬁcation. To enhance
our taxonomic resolution, 16S rRNA amplicon sequence data sets
from USA, MAL1, and MAL2 cohorts were analyzed using Resphera
Insight, a high-resolution methodology for species-level charac-
terization (see Methods).24–26 We then assessed signiﬁcant
enrichment or depletion of taxa in bioﬁlm-positive vs. bioﬁlm-
negative samples.
A limited number of speciﬁc species were identiﬁed as
differentially abundant between bioﬁlm-positive and bioﬁlm-
negative tissues (Supplementary Fig. S2). Of the four species,
one was additionally found to be enriched in right-sided vs. left-
sided samples (Clostridium ramosum), indicating a potential
association with geographical location rather than strictly bioﬁlm
status (Supplementary Fig. S3). Despite the limited number of
differences at the species level between bioﬁlm-positive and
bioﬁlm-negative tissues, a meta-analysis of functional in silico
predictions by PICRUSt revealed several bioﬁlm-associated func-
tional shifts, including an increase in gene content attributed to
cytoskeletal proteins, peptidoglycan biosynthesis, sporulation,
peptidases, novobiocin biosynthesis, and ansamycin biosynthesis,
as well as a reduction in ﬂagellar assembly genes (Fig. 2a).
Examination of taxa contributing most strongly to these functional
associations highlighted multiple, differentially abundant families
including signiﬁcant enrichment of Veillonellaceae, Lachnospir-
aceae, and Coriobacteriaceae that corresponded to the enhanced
functions in bioﬁlm-positive samples, whereas a signiﬁcant
decrease in relative abundance of Sphingomonadaceae and a
trend towards lower levels of Caulobacteraceae and Enterobacter-
iaceae contributed to reductions in ﬂagellar assembly (Fig. 2b).
Meta-analysis of microbial associations with CRC status
independent of bioﬁlms
We next examined bacterial composition independently of bioﬁlm
status in the USA, MAL1, and MAL2 cohorts. For USA and MAL1,
CRC samples were compared to both paired normal as well as
healthy biopsies, whereas for MAL2 only CRC and paired normal
tissues were examined (Fig. 3a). We observed a signiﬁcant
enrichment of the human gut commensal Bacteroides fragilis in
CRC compared to both normal ﬂanking tissue and healthy
biopsies (Fig. 3b). Additionally, four species known to be oral
pathogens were also signiﬁcantly enriched in CRC tissue:
Fusobacterium nucleatum, Parvimonas micra, Peptostreptococcus
stomatis, and Gemella morbillorum. Given this strong association
between oral pathogens and CRC, we subsequently looked for
enrichment of total oral bacteria from the Human Oral Micro-
biome Database (HOMD), a curated list of bacteria derived from
16S rRNA gene sequencing of healthy and diseased oral samples
from patients (see Supplementary Table S2 for list of species).27
This analysis revealed a robust, signiﬁcant enrichment of total
HOMD bacterial species in CRC tissue compared to both paired
normal tissue and healthy biopsies. Enrichment of the species
identiﬁed above in the tumors was not speciﬁc to tumor location;
both right-sided tumors and left-sided tumors contributed to the
enrichment of F. nucleatum, P. micra, P. stomatis, G. morbillorum,
and HOMD species (Supplementary Fig. S4). To further validate
these initial ﬁndings, we chose samples from the MAL1 cohort and
performed qPCR for the 16S rRNA gene for B. fragilis and F.
nucleatum. Read counts from the 16S rRNA amplicon sequencing
analysis for both B. fragilis and F. nucleatum signiﬁcantly correlated
with copy numbers from 16S rRNA gene qPCR (Supplementary
Fig. S5).
The above analysis was then expanded to include all available
16S rRNA gene sequencing data sets on CRC samples, including
two additional studies involving CRC versus healthy biopsy
samples,8,15 ﬁve studies on CRC versus paired normal tis-
sue,2,3,6,15,28 and four stool-based studies.4,5,9,28 In total, eight data
sets were analyzed for differences between CRC and healthy
biopsies and/or stool, and eight data sets were analyzed for
differences between CRC and paired normal tissue. Table 1
summarizes the country of origin, tissue type (stool vs. tissue
biopsy), DNA extraction method, sequencing platform, 16S rRNA
gene primers, and original ﬁndings of each publication as
reported by their respective authors prior to our meta-analysis.
Raw data sets were preprocessed using a standardized methodol-
ogy (see Methods). Collectively, this analysis encompassed
populations in North America (U.S., Canada), Europe (France,
Germany, Spain) and Asia (China, Vietnam, Malaysia), and
represented stools from 481 tumor patients and 271 healthy
Microbial features associated with CRC
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controls, as well as colon tissues from 379 tumors, 369 paired
normal tissues from tumor hosts and 172 biopsies (from 89
patients).
Enrichment of speciﬁc species in the initial USA/MAL1/MAL2
cohort analysis was validated in this expanded analysis: B. fragilis,
F. nucleatum, P. micra, P. stomatis, G. morbillorum, and the total oral
microbiome from HOMD (Fig. 4). The statistical signiﬁcance for
each individual microbe from HOMD is provided in Supplemen-
tary Table S2. We found these enrichments to be robust to
variations in normalization strategy and conﬁdence in species-
level assignment (Supplementary Fig. S6). The stool studies also
supported these ﬁndings, although the signal was weaker in
comparison to the robust differences seen in tissues (Fig. 4).
Although others have reported an enrichment of fusobacterial
species and the enterotoxigenic strain of B. fragilis in late-stage
tumors,29,30 we did not observe any consistent changes with
respect to F. nucleatum, B. fragilis, HOMD, or combinations of these
species and tumor stage (Supplementary Fig. S7). Conversely,
several Bacteroides species (B.vulgatus, B. dorei, and B. stercoris) as
well as Faecalibacterium prausnitzii were consistently depleted in
CRC compared to healthy biopsies and paired normal tissues
(Supplementary Fig. S8).
Not all fusobacterial species are enriched in CRC
The expanded meta-analysis also uncovered signiﬁcant enrich-
ment of additional fusobacterial species F. necrophorum, F.
periodonticum, and L. trevansanii in CRC samples compared to
healthy biopsies (Fig. 5a). However, there were several other
species within the fusobacteria phylum that were not enriched in
CRC and were in some cases more highly abundant in the healthy
tissues. Fusobacteria not associated with CRC included F.
necrogenes, F. mortiferum, F. varium, and F. ulcerans (Fig. 5b).
Additionally, two healthy biopsy patients from Malaysia (MAL1)
harbored very high levels of the Fusobacteriaceae member
Cetobacterium somerae (>20% relative abundance of all reads;
Fig. 5c). Such data highlight the importance of detection down to
the species level, as only a subset of the genus Fusobacterium was
associated with CRC and an analysis limited to genera would
therefore have resulted in a less robust or even non-signiﬁcant
signal. Moreover, the highly abundant intestinal commensal
Faecalibacterium prausnitzii was originally classiﬁed as Fusobacter-
ium prausnitzii until 2002;31 had this species not been reclassiﬁed,
it would have strongly confounded genus and higher-level signals
associated with CRC.
Compilation of all microbial features of CRC
Finally, we assessed the combined prevalence of bioﬁlms, B.
fragilis, and oral microbes from HOMD in order to determine the
percentage of CRC tumors with at least one feature of microbial
dysbiosis. We selected samples for which data on all three
microbial features were available (i.e., samples from the USA,
MAL1 and MAL2 cohorts). We deﬁned enrichment of B. fragilis as
tumors with B. fragilis relative abundance >2% of overall
sequences, and enrichment of HOMD as tumors having HOMD
bacteria present at >10% of overall sequences; these cut off points
excluded >90% of healthy biopsies. Tumors harbored the highest
percentages of all three features: 49% were bioﬁlm-positive, 48%
were HOMD positive, and 38% were B. fragilis positive (Fig. 6a).
While a similar percentage of paired normals were bioﬁlm positive
(44%, p = 0.721 by Fisher’s exact test compared to tumors), the
prevalence of HOMD and B. fragilis in paired normal tissues was
approximately half of that found in tumors, signiﬁcantly so for
HOMD (HOMD: 24 vs. 48%, p = 0.009; B. fragilis: 17 vs. 38%, p =
0.254, respectively; Fig. 6a). Only 2/11 paired normal tissues that
were positive for B. fragilis had tumors that were below the cut-off
value, while similarly 3/15 paired normal tissues that were positive
for HOMD had tumors below the HOMD cut-off value. Of the 33
healthy biopsies randomly chosen for sequencing, representing
left and right biopsies from 16 patients and one biopsy from the
right side of a 17th patient, only 6% were bioﬁlm positive (2/33),
with both bioﬁlms occurring on right-sided biopsies from the
MAL1 cohort (Supplementary Table S1). Three percent of the
biopsies were enriched for HOMD organisms, and 0% were
enriched for B. fragilis. These percentages were signiﬁcantly lower
Fig. 2 Microbial associations with bioﬁlm status. Frozen tissue from USA, MAL1, and MAL2 cohorts were characterized by 16S rRNA amplicon
sequencing. a Top panel: bioﬁlm positive CRC and normal ﬂanking tissues demonstrated several functional shifts in the bacterial composition,
including increases in gene content associated with cytoskeletal proteins, peptidoglycan biosynthesis, sporulation, and ﬂagellar assembly
based on PICRUSt analysis. Bottom panel: the bacterial families Veillonellaceae, Coriobacteriaceae, and Lachnospiraceae were enriched in
bioﬁlm-positive samples, while Sphingomonadaceae was enriched in bioﬁlm-negative samples. Random-effects models with 95% CI above or
below 0 (red diamonds) were considered statistically signiﬁcant. Hedge’s g difference statistic is shown on the X axes. The ﬁxed effects model
assumes there exists a single effect size shared by all included studies, while the random effects model allows for variation in the effect size
from study to study. Heterogeneity analysis includes estimates of I2 (percentage of variation reﬂecting true heterogeneity), τ2 (random-effects
between study variance), and p-value from Cochran’s Q test for heterogeneity. b The functional alterations due to bioﬁlm status were linked to
multiple, differentially abundant families (f ) and genera (g) in the bioﬁlms
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Fig. 3 Associations of B. fragilis and human oral microbiota with CRC status for USA, MAL1, and MAL2 cohorts. Microbiome proﬁling with 16S
rRNA gene sequencing was applied to tumor (CRC) and paired normal tissues (Normal) from CRC patients for all three cohorts, as well as
healthy biopsies (Healthy Bx) for USA and MAL1. a Bar charts of microbial sequence relative abundance for B. fragilis and bacteria from the
Human Oral Microbiome Database (HOMD) from the three 16S rRNA amplicon data sets: USA (top panel), MAL1 (middle panel), and MAL2
(bottom panel). Each vertical bar represents an individual patient. b B. fragilis as well as the oral pathogens F. nucleatum, P. micra, P. stomatis, G.
morbillorum, and the overall consortia associated with the Human Oral Microbiome Database (HOMD) were all found to be signiﬁcantly
enriched in tumor specimens compared to biopsies from healthy patients without cancer (top panel), and compared to normal ﬂanking tissue
(bottom panel). Random-effects models with 95% CI above or below 0 (red diamonds) were considered statistically signiﬁcant. Hedge’s g
difference statistic is shown on the X axes. The ﬁxed effects model assumes there exists a single effect size shared by all included studies, while
the random effects model allows for variation in the effect size from study to study. Heterogeneity analysis includes estimates of I2
(percentage of variation reﬂecting true heterogeneity), τ2 (random-effects between study variance), and p-value from Cochran’s Q test for
heterogeneity
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than the percentages observed for paired normals and tumors for
each feature by Fisher’s exact test (healthy biopsy vs. paired
normal: p < 0.0001 for bioﬁlms, p < 0.01 for HOMD, p < 0.01 for B.
fragilis; healthy biopsy vs. tumor: p < 0.0001 for all three features).
In addition to having the highest percentages of each individual
microbial feature above, an abundance of tumors (27/63 or 43%
total) harbored more than one feature (41% single, 35% two, and
8% three features) (Fig. 6b). When tumors were analyzed
according to their anatomical location, right-sided tumors, not
unexpectedly, displayed more bioﬁlm-related categories, while the
predominant phenotype of left-sided tumors reﬂected the co-
occurrence of B. fragilis and HOMD (Supplementary Fig. S9). In
contrast to the tumors, paired normal tissue contained mostly
single features (51% single, 17% two, and 0% three features), with
the majority of those harboring more than one feature also having
tumors with more than one feature (8/11). The healthy biopsies
contained only single features (6% bioﬁlm only, 3% HOMD only)
and were otherwise absent of any dysbiosis (91% no features).
Overall, 84% of tumors harbored at least one measure of microbial
dysbiosis associated with CRC status as deﬁned in our meta-
analysis, compared to 68% of paired normal tissues and only 9% of
healthy biopsies.
DISCUSSION
Overall, our meta-analysis demonstrates that the vast majority
(>80%) of CRC cases contain aberrant microbial signatures
indicative of dysbiosis. Our high-resolution 16S rRNA gene meta-
analysis captured species-level taxonomic assignments, allowing
for the most detailed map to date of the microbial dysbiosis in
CRC. These data support multiple avenues by which bacteria may
promote carcinogenesis, including enrichment of a symbiote with
enterotoxigenic capabilities (B. fragilis), the emerging role of oral
microbes as potentially hostile guests in the gut, and the
establishment of polymicrobial, procarcinogenic bioﬁlms.16,32,33
Additionally, while speciﬁc organisms, such as B. fragilis and F.
nucleatum have been implicated by individual studies using
alternative methods such as metagenomic sequencing or qPCR,
the present meta-analysis pipeline enabled consistent detection of
these species by 16S rRNA gene sequencing—often in cases
where the original authors’ ﬁndings were restricted to genus-level
ﬁndings—regardless of the sequencing platform, 16S rRNA gene
primer set, or DNA extraction method used. Importantly, the
microbial features detected in our study were not mutually
exclusive and in fact were often found to co-occur in patients in
our meta-analysis. However, whether these microbial features are
required for the initiation or progression of tumorigenesis or
whether they are merely bystanders remains to be elucidated.
B. fragilis is a well-studied human gut symbiont, making its
enrichment associated with CRC status potentially surprising.
However, enterotoxigenic strains of B. fragilis (ETBF) harboring the
B. fragilis toxin (BFT) have long been associated with diarrheal
disease and, potentially, inﬂammatory bowel disease and CRC.30,34
Mouse and in vitro studies have shown that BFT likely promotes
Fig. 4 Expanded differential relative abundance meta-analysis supports species-level ﬁndings. A meta-analysis of a CRC tissue or stool vs.
healthy biopsy or stool and b CRC vs. ﬂanking normal tissues supports the enrichment of B. fragilis and oral microbes in CRC. Random-effects
models with 95% CI above or below 0 (red diamonds) were considered statistically signiﬁcant. Hedge’s g difference statistic is shown on the X
axes. The ﬁxed effects model assumes there exists a single effect size shared by all included studies, while the random effects model allows for
variation in the effect size from study to study. Heterogeneity analysis includes estimates of I2 (percentage of variation reﬂecting true
heterogeneity), τ2 (random-effects between study variance), and p-value from Cochran’s Q test for heterogeneity
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tumorigenesis by inducing (1) DNA damage through enhanced
spermine oxidase and resulting ROS activity,35 and (2) cleavage
and subsequent degradation of the tumor suppressor E-cadherin,
resulting in increased permeability of the colonic epithelium,
enhanced Wnt/β-catenin signaling, and enhanced cellular pro-
liferation.36,37 In mouse models, inoculation of ETBF into ApcMin/+
mice accelerates tumorigenesis in an IL-17-dependent manner.38
In patients, bft has been found to be present more frequently in
CRC versus controls in both the colon mucosa (>85 vs. 53%)30 and
in the stool (38 vs. 12%, and 27 vs. 10%).39,40 Thus, the association
between enrichment of B. fragilis and CRC observed in our meta-
analysis may in fact reﬂect enrichment of ETBF strains of B. fragilis
in the gut. Importantly, the enrichment of B. fragilis was paralleled
by depletion of several other Bacteroides members, which is
consistent with reports by others of an overall loss of phylum
Bacteroidetes3 and more speciﬁcally the genus Bacteroides.9,12 The
selective enrichment of B. fragilis may therefore suggest a growth
advantage of B. fragilis over other Bacteroides species during
tumorigenesis, and further highlights the importance of species-
level resolution.
Our meta-analysis also revealed a robust enrichment of F.
nucleatum and other oral species in CRC compared to both paired
normal and healthy biopsy tissues. These data are consistent with
a recent meta-analysis by Shah et al. in stool samples in which
Parvimonas micra and two separate unclassiﬁed Fusobacterium
were reported to be enriched in stools from CRC patients
compared to healthy controls.41 However, that study was unable
to identify F. nucleatum speciﬁcally, likely due to the signal being
weaker in stool compared to tissue and/or the enhanced
resolution of our meta-analysis pipeline compared to the strain
select tool SS-UP used in that study. F. nucleatum has gained
increasing notoriety in recent years as a potential pathogen in a
number of clinical diseases including gastro–intestinal disorders,
cardiovascular disease, adverse pregnancy outcomes, respiratory
tract infections, and oropharyngeal infections, where it was ﬁrst
discovered.42 Mechanistically, F. nucleatum is a ubiquitous oral
bacterium that is both highly adherent and invasive, a property
attributed to virulence proteins including the adhesion and
invasion protein, FadA, and the galactose-inhibitable adhesion
protein Fap2.43–45 More recently, secreted or surface FadA was
found to bind to E-cadherin and induce Wnt/β-catenin signaling in
the colons of mice, where F. nucleatum accelerated tumorigen-
esis.46,47 Immune mechanisms including myeloid cell inﬁltration,
the balance between FOXP3hi and FOXP3lo Treg populations, and
checkpoint molecule (TIGIT) blockade may modulate F. nucleatum-
associated carcinogenesis.47–50
However, Fusobacterium are enriched in only a subset of tumors
and are present at a much lower abundance in paired normal
tissue.3,13,46,51–53 Similarly, enrichment of Fusobacterium in bioﬁlms
occurs in only a subset of tumors and is often undetectable in
paired normal tissues,16 ﬁndings that our additional cohort of
Malaysian patients and meta-analyses upheld. As most carcino-
genic mechanisms are predicted to be elevated in adjacent
normal tissue as well as the tumor itself, in line with the cancer
hypothesis that it takes years or even decades for cancer to
develop within normal colon tissue, these data question whether
F. nucleatum is an important initiator of carcinogenesis. Instead, F.
nucleatum may be uniquely suited to grow and contribute to
tumor progression in an established tumor microenvironment,
due to the microbe’s highly adherent and invasive nature that
could exploit a compromised colonic epithelial cell (CEC) layer.
Further, as Kostic et al. have proposed, the asaccharolytic
metabolism of F. nucleatum would not compete for glucose
consumption by the tumor, and the anaerobic nature of F.
nucleatum would enable it to tolerate the hypoxic tumor
environment.47 F. nucleatum may even provide a growth
advantage for the tumor, due to the bacteria’s ability to inhibit
NK cell-mediated tumor cell death via binding of the bacterial
protein Fap2 to one of the NK cell inhibitory receptors, TIGIT.50 The
procarcinogenic capability of F. nucleatum in the gut may be
Fig. 5 Not all fusobacterial species are associated with CRC. a In addition to F. nucleatum, we detected signiﬁcant enrichment of F.
necrophorum, F. periodonticum, and L. trevansanii in CRC tissue or stool compared to healthy biopsies or stool. Hedge’s g difference statistic is
shown on the X axes. The F. periodonticum forest plot includes ambiguous assignments (see Methods). b Other fusobacterial species were not
differentially abundant between CRC and healthy patients. The ﬁxed effects model assumes there exists a single effect size shared by all
included studies, while the random effects model allows for variation in the effect size from study to study. Heterogeneity analysis includes
estimates of I2 (percentage of variation reﬂecting true heterogeneity), τ2 (random-effects between study variance), and p-value from Cochran’s
Q test for heterogeneity. c Bar chart of all detected species within the fusobacterial phylum and their total sequence relative abundances in
the MAL1 cohort. Each vertical bar represents an individual patient. Several healthy Malaysian patients in the MAL1 cohort harbored high
levels of fusobacterial species not associated with CRC
Microbial features associated with CRC
JL Drewes et al.
8
npj Biofilms and Microbiomes (2017)  34 Published in partnership with Nanyang Technological University
highly strain-dependent, as some strains have been resistant to
colonization in mouse gut and required daily inoculation47 while
others have been found to colonize readily.49
F. nucleatum is frequently found to co-occur with other oral
pathogens in CRC53 and can coaggregate with members of all
genera in vitro.54 As such, F. nucleatum may be a bridging
organism that assists in the colonization of other microbes
through its myriad adhesins, which allow other microbes to
adhere to and interact with F. nucleatum.42,55 Our meta-analysis
revealed consistent elevations in not only F. nucleatum but also
several other oral pathogens (e.g., P. micra and P. stomatis) in CRC
compared to paired normal tissue and healthy biopsy controls. A
variety of other oral microbes were frequently detected as well,
including several Fusobacteriaceae that were enriched in normal
ﬂanking tissues compared to CRC from Malaysian patients. Flynn
et al. have elegantly proposed a polymicrobial model in which
several oral pathogens, reliant on each other for survival, may
establish a niche in the gut that may contribute to tumorigenesis
due to similarities between the gut and the oral environment such
as similar pH and propensity to form bioﬁlms.33 Initiation or
progression of tumorigenesis becomes beneﬁcial to these bacteria
because of increased nutrients from local inﬂammatory responses.
These organisms include Fusobacterium, Parvimonas, and Peptos-
treptococcus species found to be enriched in CRC in our meta-
analysis, as well as Porphyromonas, Prevotella, and Gemella species
enriched in other studies.5,9,15
While it is tempting to speculate that bioﬁlms from the oral
cavity containing F. nucleatum seed the gut bioﬁlms that we have
observed in a substantial number of CRC cases, this likely would
only account for a subset of bioﬁlm formation events. Sparsely
populated (<5 bacteria per 200 μm2 area) Fusobacterium could be
detected in almost all of the bioﬁlms from Malaysia by FISH, but
dense fusobacterial aggregates were abundant in only 25% of the
tumor bioﬁlms, were infrequently detected in bioﬁlms on paired
normal tissue, and were not detected on any healthy biopsies. By
sequencing, approximately only one-third of bioﬁlm-positive
tumors were enriched for oral consortia derived from the HOMD,
while <10% of bioﬁlm-positive paired normal tissues and 0% of
bioﬁlm-positive healthy biopsies (N = 2) contained HOMD levels of
an appreciable relative abundance. These data suggest that oral
bacteria such as F. nucleatum are not required for bioﬁlm
formation in the gut and that therefore the initiating species
may be different from that of oral bioﬁlms.
Certainly, further studies on how and why bioﬁlms form in the
human gastrointestinal tract are necessary. The data thus far
support a role for bioﬁlms in causality of a subset of CRC,
particularly right-sided CRC, where nearly 100% of tumors and
paired normal tissue have been found to be covered in invasive,
polymicrobial bioﬁlms adjacent to the CEC layer. In comparison, a
range of 13–35% of healthy screening colonoscopy patients have
been reported to harbor colonic bioﬁlms, with equivalent
percentages of bioﬁlms on the right and left sides.16,23 Notably,
the prevalence of bioﬁlms in the healthy biopsies in the present
meta-analysis was lower than expected (6%); however, separating
these samples by cohort revealed that 2/12 MAL1 biopsies (17%)
were bioﬁlm positive, while the 21 USA biopsies chosen for
sequencing were part of a larger cohort previously published in
which 15/120 biopsies (13%) were bioﬁlm positive.16 Clearly there
Fig. 6 Combined prevalence of CRC-associated microbial features in USA, MAL1, and MAL2 cohorts. Positive status for B. fragilis and the
human oral microbes from the HOMD database were deﬁned as a relative abundance >2 and >10% of all 16S rRNA gene sequences,
respectively. a Percentage of healthy biopsies, paired normal, and tumor tissues that were positive for each microbial feature (bioﬁlms, HOMD,
and B. fragilis). Statistics shown are Fisher’s exact test. *p< 0.01, ***p< 0.001. b Percentage and overlap of healthy biopsies, paired normal, and
tumor tissues harboring one, two, three or no microbial features
Microbial features associated with CRC
JL Drewes et al.
9
Published in partnership with Nanyang Technological University npj Biofilms and Microbiomes (2017)  34 
is a need for a much larger study of bioﬁlms in healthy screening
colonoscopy individuals to resolve the true estimated prevalence,
but the current estimates still point to a much higher rate of
bioﬁlms on proximal tumors than on proximal biopsies. The
potential procarcinogenic mechanisms of bioﬁlms elucidated thus
far include production of the polyamine (N)1, (N)12-diacetylsper-
mine56 and induction of a pro-inﬂammatory response involving
enhanced epithelial levels of IL-6, phospho-STAT3, and increased
crypt epithelial cell proliferation.16 Importantly, one cannot predict
bioﬁlm status from sequencing data alone. For bioﬁlm-negative
tissues, sequencing likely detected bacteria enmeshed in the
loose, permissive outer mucus layer, a distance from the CECs,
whereas, for bioﬁlm-positive tissues, bacteria invading the dense,
restrictive mucus layer adjacent to the CECs were also detected.
Thus, the limited changes in bacterial composition that we
observed between bioﬁlm-positive and bioﬁlm-negative samples
suggest that the close proximity of the bacteria to the CEC layer
and changes in their function within a bioﬁlm (Fig. 2) may be more
important to changes in CRC biology than the composition of the
bioﬁlm itself.
Overall, our meta-analysis of microbial features in CRC conﬁrms
three separate but partially overlapping dysbiotic mechanisms:
enrichment of B. fragilis, enrichment of oral microbes such as F.
nucleatum, and a high prevalence of invasive, polymicrobial
bioﬁlms. Strengths of the 16S rRNA gene meta-analysis in
particular include the fact that these commonalities were found
in patients from several different countries in North America,
Europe, and Asia, using a wide range of sample preparation
techniques and 16S rRNA gene sequencing technologies. The
implementation of a high-resolution, consistent analysis metho-
dology greatly improved our ability to detect species-level
changes compared to the original authors’ ﬁndings, which were
largely restricted to genus-level associations (see Fig. 4 vs. Table 1),
as well as compared to the recent stool meta-analysis by Shah
et al.41 Additionally, samples from not only tumors and paired
normal tissue but also healthy biopsies and stool samples were
included in the analysis. A similar strength of signal was obtained
when comparing CRC vs. paired normal (tissues only) or CRC vs.
healthy (tissues and stool), although the latter displayed more
heterogeneity by I2 values. However, the stool samples displayed
weaker associations than tissues, suggesting that a tissue-based
approach would be required for potential biomarker studies
involving the identiﬁed microbial features. Weaknesses include
the fact that the present analysis did not take into account the
concepts of mucosal-associated bacterial co-abundance groups57
or metacommunities,15 which may represent another layer of
complexity in the microbiome-CRC hypothesis, although our
analysis of total HOMD microbes likely parallels a metacommunity
phylotype in the latter study. Furthermore, we did not analyze
expression of virulence factors, which are an important nuance of
bacterial genetics. Despite these limitations, our data strongly
support a clear association between multiple, non-mutually
exclusive forms of microbial dysbiosis and a substantial portion
of CRC cases (>80%). While we should be cautious in attributing
the evolution of carcinogenesis to microbes, deﬁning the subset
of patients that may be at risk of microbiome-associated CRC
tumorigenesis could be a major turning point in CRC prevention,
detection, and treatment. Prospective studies will be necessary to
conﬁrm that bioﬁlms, B. fragilis, and oral pathogens confer an
increased risk of CRC.
METHODS
Ethical statement
This study was approved by the University of Malaya Medical Centre
(UMMC, Kuala Lumpur, Malaysia) Medical Ethics Committee (Ref No.
1066.38) and the Johns Hopkins Institutional Review Board. All samples
were obtained in accordance with the Health Insurance Portability and
Accountability Act. Blank consent forms for the US and Malaysian cohorts
(the latter provided in Malay and English) are available in the
Supplementary Information. This research was conducted in accordance
to all relevant guidelines and procedures.
Sample collection
The approach to collection of colon tissues for the USA, MAL1 and MAL2
cohorts has been previously described.16 The proximal colon through the
hepatic ﬂexure was deﬁned as right colon, and distal to the hepatic ﬂexure
as left colon. Samples from MAL1 and MAL2 were maintained as
independent cohorts because 16S rRNA amplicon sequencing was
performed at different facilities with different methodologies for the two
sets of samples. Individuals who had received pre-operative radiation,
chemotherapy or had a personal history of CRC or inﬂammatory bowel
disease were excluded. All patients underwent a standard mechanical
bowel preparation. Standard pre-operative intravenous, but not oral,
antibiotics were administered in all surgical cases. Demographic and
histopathology information of the study subjects are summarized in
Supplementary Table S1.
Study data were collected and managed using REDCap electronic data
capture tools58 hosted at Johns Hopkins University.
FISH analysis of bioﬁlms
FISH was performed on Carnoy’s-ﬁxed, parafﬁn-embedded tissue sections
from the Malaysian patients as previously described, with minor
modiﬁcations16 (see SI Methods). Samples were screened in a randomized,
blinded fashion.
16S rRNA gene Illumina library generation and sequencing
For the MAL1 cohort, a total of 54 samples were evaluated for sequencing,
including paired left-right biopsies from six healthy patients, paired tumor/
normal samples from 20 CRC patients, and an additional two unpaired
tumors from two CRC patients. One polyp was sequenced but excluded
from analysis. DNA was extracted using the ZR Fecal DNA MiniPrep kit
(Zymo Research) with modiﬁcations (see SI Methods). High-throughput
next-generation sequencing of the V3-V4 hypervariable region of the 16S
rRNA gene was performed using 319 F (5′-ACTCCTACGGGAGGCAGCAG-3′)
and 806 R (5′-GGACTACHVGGGTWTCTAAT-3′) universal primers containing
a linker sequence required for Illumina MiSeq 300 bp paired-end
sequencing and a 12-bp heterogeneity-spacer index sequence.59,60
For the MAL2 cohort, a total of 46 samples, including paired tumor/
normal colon tissue samples from 19 CRC patients, two unpaired tumors
from CRC patients, and biological replicates of three MAL1 paired tumor/
normal samples were evaluated. Removal of the biological replicates from
either MAL1 or MAL2 did not inﬂuence statistical signiﬁcance of the
analysis (Supplementary Fig. S10). DNA was extracted using the
MasterPure DNA Puriﬁcation Kit (Epicentre/Illumina). The V3-V4 region of
the 16S rRNA gene was ampliﬁed using S-D-Bact-0341-b-S-17 forward (5′-
NNNNCCTACGGGNGGCWGCAG-3′) and S-D-Bact-0785-a-A-21 reverse (5′-
GACTACHVGGGTATCTAATCC-3′) primers61 designed to include the
Illumina-compatible adapters.62 SI Methods contain additional details of
library generation and sequencing.
Analysis of all 16S rRNA amplicon sequence data sets
Data sets generated utilizing paired-end sequencing on the Illumina
platform were ﬁrst processed as follows: raw paired-end reads were
merged into consensus fragments by FLASH63 requiring a minimum 20 bp
overlap with 5% maximum mismatch density, and subsequently ﬁltered for
quality (targeting error rates <1%) and length (minimum 150 bp) using
Trimmomatic64 and QIIME.65,66 Spurious hits to the PhiX control genome
were identiﬁed using BLASTN and removed.
Data sets generated utilizing Roche/454 sequencing were ﬁrst
preprocessed as follows: sequences were de-multiplexed using 5′ barcode
identiﬁers and ﬁltered for quality and length in QIIME65,66 requiring: (i)
trimming of the ﬁrst 15 bp window with a mean Phred quality score below
24, (ii) a maximum homopolymer run of eight nucleotides, and (iii) a
minimum ﬁnal length of 150 bp. Passing sequences were error-corrected
using Acacia with default parameters.67
Resulting sequences from all sequencing technologies were then
trimmed of their associated primers, evaluated for chimeras with UCLUST
(de novo mode),68 and screened for human-associated contaminant using
Bowtie269 searches of NCBI Homo sapiens Annotation Release 106 followed
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by a BLASTN search against the GreenGenes 16S database (v13.05)70 to
identify unaligned host-associated sequences. Reads assigned to chlor-
oplast or mitochondrial contaminants by the RDP classiﬁer71 with a
minimum conﬁdence of 50% were removed.
High-quality 16S sequences were assigned to a high-resolution
taxonomic lineage using Resphera Insight (Baltimore, MD).24–26 Sequences
were also analyzed by PICRUSt72 to infer functional content. Species
associated with the human oral tract were determined from the HOMD.27
Details of Resphera Insight speciation validation, benchmarking studies
and statistical analyses are available in SI Methods.
Code availability
Open source R code used for meta-analyses is available from the authors
upon request.
Data availability
Raw sequences from new cohorts (MAL1 and MAL2) have been deposited
in the NCBI SRA repository (BioProject accession no. PRJNA325649 and
PRJNA325650). Primary sequencing data are available upon request.
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